Associations among interleukin-17, interferon-gamma, and acute coronary syndrome.

Yongbiao Zhang2#, Yun Ren1#, Lingxia Mu2, Jin Huang2, Chao-Chao Bai2, Guangsheng Du1,2*

1The Fifth People's Hospital of Foshan, Foshan, PR China
2Department of Cardiology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang, PR China

#These authors equally contributed to the work

Abstract

Currently, cardiovascular disease is the second highest cause of death globally. The occurrence and development of Acute Coronary Syndrome (ACS) have attracted attention, and inflammation has been found to play an important role in the occurrence and development of ACS. We investigated the roles of interleukin-17 (IL-17) and interferon-gamma (IFN-γ), as well as their relationship, in patients with ACS. We analysed the dynamic changes in IL-17 and IFN-γ levels in patients with ACS before and after Percutaneous Coronary Intervention (PCI). Patients were divided into the following 3 groups: (1) an Acute Myocardial Infarction (AMI) group (n=30), (2) an Unstable Angina Pectoris (UAP) group (n=30), and (3) a control group (n=30). We found that the IL-17 and IFN-γ levels were higher in the AMI and UAP groups than those in the control group. However, no significant association was observed between IL-17 and IFN-γ levels and the degree of coronary artery stenosis. A low correlation was found between IL-17 and IFN-γ levels before treatment; however, no correlation was detected after treatment. In the AMI and UAP groups, IL-17 and IFN-γ levels were significantly lower after PCI than those before PCI. IL-17 and IFN-γ may play a central role in the occurrence and development of ACS; however, their levels may not reflect disease severity. Additionally, IL-17 and IFN-γ may act synergistically in ACS. Moreover, the clinical symptoms in patients with ACS can be alleviated and inflammation in the body can be reduced through PCI.

Keywords: Acute coronary syndrome, Interleukin-17, Interferon-gamma, Correction.

Introduction

Currently, cardiovascular disease is one of the leading causes of mortality worldwide and atherosclerosis is one of the most common cardiovascular diseases. Specifically, atherosclerosis and Acute Coronary Syndrome (ACS) have been shown to be associated with the rupture of vulnerable lesions, atherothrombosis, and vessel occlusion [1-3]. Chronic autoimmune processes predominantly involving macrophages, T lymphocytes, and dendritic cells have been shown to play important roles in atherogenesis and the development of ruptured lesions [4-10]. The mechanism of inflammation in Coronary Heart Disease (CHD) is complicated, and the Interleukin-17 (IL-17) family, a group of inflammatory factors, has gained attention for its role in this mechanism [11]. The IL-17 family plays central roles in various arms of the adaptive immune system and these inflammatory factors are important for understanding cytokine networks. IL-17A-F and IL-17A (hereafter referred to as IL-17) are the most widely studied members of the IL-17 family [12-15]. IL-17 family proteins originate from diverse cellular sources and have been shown to be specifically associated with IL-17A [13]. IL-17, the primary cytokine secreted by TH17 cells, was initially found to be associated with memory CD4 T cells and was later found to be also associated with CD8 T-cells, γ δ T cells, and NK cells [14-18]. IL-17 has been shown to have proinflammatory effects on a broad range of cellular targets, including epithelial and endothelial cells, fibroblasts, osteoblasts, and monocytes/macrophages [14].

The levels of Interferon-gamma (IFN-γ), a type II interferon, are high in the coronary arteries of patients with atherosclerosis [19]. Additionally, IFN-γ plays an important role in the process of T cell-mediated injury and remodeling of human coronary arteries [20]. The contribution of IFN-γ in atherosclerosis is complicated; however, its pro-atherogenic role has been clarified [21]. IFN-γ produced by CD4+ Th1 cells, CD8+ cytolytic T cells, and NK cells helps IL-17 induce the production of pro-inflammatory cytokines and chemokines that act on vascular smooth muscle cells to promote secondary pro-arteriosclerotic vascular changes [22]. Although the roles of IL-17 and IFN-γ in atherosclerosis have been studied, the relationship between IL-17 and IFN-γ remains controversial.
the present study, we investigated the roles of IL-17 and IFN-γ, and their relationship in patients with ACS. Additionally, we analysed the dynamic changes in IL-17 and IFN-γ levels in these patients before and after percutaneous transluminal coronary angioplasty (PCI).

Patients and Methods

Patients

The study included 60 patients with ACS who underwent PCI between 2014 and 2015. All patients were less than 75 years of age and belonged to the Asian Han ethnic group. Patients with the following diseases were excluded: severe heart failure, malignant tumor, acute and chronic infections, autoimmune disease, severe liver disease, and reduced kidney function. According to the WHO classification of CHD, patients were divided into an Acute Myocardial Infarction (AMI) group (n=30; mean age, 55.3 ± 10.4 years; 86.7% male) and Unstable Angina Pectoris (UAP) group (n=30; mean age, 60.1 ± 10.1 years; 90% male). Patients in these groups were diagnosed and treated according to the guidelines established in 2001 and modified in 2014 by the cardiovascular disease branch of The Chinese Medical Association. All patients underwent PCI as standard treatment. A total of 30 individuals with unexplained chest distress and no CHD on routine examination and coronary angiography were selected as the control group (mean age, 53.4 ± 10.2 years; 66.7% male). The baseline characteristics of three groups are shown in Table 1. The demographics of the AMI and UAP groups were similar; however, the number of male patients was significantly lower in the control group than that in the AMI and UAP groups. Patients were treated with clopidogrel bisulfate tablet, aspirin enteric-coated metformin hydrochloride, tirofiban hydrochloride, balloon expansion, and drug-coated stents in the AMI and UAP groups. Preoperative iodine allergy tests were carried out. Iodixanol was injected as the contrast agent in the three groups.

Table 1. Comparison of baseline characteristics among three groups.

<table>
<thead>
<tr>
<th>Item</th>
<th>AMI Group (n=30)</th>
<th>UAP Group (n=30)</th>
<th>Control group (n=30)</th>
<th>F/x</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (case)</td>
<td>15 (50%)</td>
<td>15 (50%)</td>
<td>15 (50%)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Age (case)</td>
<td>55.3 ± 10.40</td>
<td>60.1 ± 10.10</td>
<td>53.4 ± 10.20</td>
<td>3.287</td>
<td>0.42</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74.13 ± 7.43</td>
<td>73.60 ± 8.66</td>
<td>71.37 ± 11.29</td>
<td>0.735</td>
<td>0.474</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.72 ± 0.06</td>
<td>1.70 ± 0.07</td>
<td>1.68 ± 0.07</td>
<td>2.381</td>
<td>0.098</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.13 ± 1.90</td>
<td>25.29 ± 2.18</td>
<td>25.17 ± 2.70</td>
<td>0.037</td>
<td>0.963</td>
</tr>
<tr>
<td>Smoke (case)</td>
<td>24 (80.0%)</td>
<td>21 (70.0%)</td>
<td>14 (47%)</td>
<td>1.97</td>
<td>0.146</td>
</tr>
<tr>
<td>Hypertension (case)</td>
<td>13 (43.33%)</td>
<td>19 (63.33%)</td>
<td>14 (46.67%)</td>
<td>1.375</td>
<td>0.258</td>
</tr>
<tr>
<td>Diabetes (case)</td>
<td>3 (10.0%)</td>
<td>3 (10.0%)</td>
<td>1 (3.33%)</td>
<td>1.239</td>
<td>0.538</td>
</tr>
<tr>
<td>Alanine aminotransferase (IU/L)</td>
<td>36.97 ± 24.50</td>
<td>27.60 ± 28.78</td>
<td>20.73 ± 13.13</td>
<td>3.67</td>
<td>0.03</td>
</tr>
<tr>
<td>Aspartate transferase (IU/L)</td>
<td>88.07 ± 105.05</td>
<td>22.50 ± 24.54</td>
<td>18.73 ± 7.41</td>
<td>11.686</td>
<td>0</td>
</tr>
<tr>
<td>Urea nitrogen (mmol/L)</td>
<td>4.96 ± 1.88</td>
<td>5.71 ± 2.12</td>
<td>4.81 ± 1.00</td>
<td>2.326</td>
<td>0.104</td>
</tr>
<tr>
<td>Creatinine (mmol/L)</td>
<td>90.30 ± 53.33</td>
<td>81.06 ± 19.65</td>
<td>72.62 ± 10.66</td>
<td>2.107</td>
<td>0.128</td>
</tr>
<tr>
<td>Fasting glucos (mmol/L)</td>
<td>6.14 ± 2.51</td>
<td>5.85 ± 2.41</td>
<td>4.80 ± 0.86</td>
<td>3.468</td>
<td>0.036</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)</td>
<td>1.62 ± 0.76</td>
<td>1.54 ± 0.82</td>
<td>1.64 ± 0.89</td>
<td>0.103</td>
<td>0.903</td>
</tr>
<tr>
<td>Low density lipoprotein (mmol/L)</td>
<td>2.72 ± 0.70</td>
<td>2.48 ± 0.90</td>
<td>2.29 ± 0.74</td>
<td>1.982</td>
<td>0.145</td>
</tr>
<tr>
<td>High density lipoprotein (mmol/L)</td>
<td>0.91 ± 0.23</td>
<td>1.00 ± 0.23</td>
<td>1.06 ± 0.27</td>
<td>2.293</td>
<td>0.108</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.15 ± 0.88</td>
<td>4.07 ± 1.10</td>
<td>3.89 ± 0.88</td>
<td>0.502</td>
<td>0.607</td>
</tr>
<tr>
<td>White cell</td>
<td>12.6 ± 1.9 × 10⁶ g/L</td>
<td>10.6 ± 0.6 × 10⁶ g/L</td>
<td>5.7 ± 0.4 × 10⁶ g/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red cell</td>
<td>145.7 ± 20.1 g/L</td>
<td>137.2 ± 10.3 g/L</td>
<td>131.9 ± 7.8 g/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitive c-reactive protein</td>
<td>6.7 ± 1.5 mg/L</td>
<td>2.6 ± 1.3 mg/L</td>
<td>2.3 ± 1.3 mg/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine kinase</td>
<td>435.0 ± 128.1 ng/ml</td>
<td>78.0 ± 40.0 ng/ml</td>
<td>90.8 ± 34.0 ng/ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CK-MB</td>
<td>36.2 ± 24 ng/ml</td>
<td>9.4 ± 2.6 ng/ml</td>
<td>10.0 ± 3.0 ng/ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troponin I</td>
<td>4.78 ± 2.6 ng/ml</td>
<td>0.09 ± 0.02 ng/ml</td>
<td>0.04 ± 0.03 ng/ml</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Cell preparation and reagents

In the AMI and UAP groups, blood samples were collected in EDTA tubes before PCI and on the day of leaving the hospital, while in the control group, blood samples were collected before coronary angioplasty. Plasma was separated by centrifugation at 3000 rpm for 10 min at 4°C and stored at -80°C until analysis.

ELISA

The plasma IL-17 and IFN-γ levels were determined using ELISA kits (Cloud-Clone Corp., Houston, TX, USA), according to the manufacturer’s instructions. The detection range of the kits for IL-17 and IFN-γ was 15.6-1000 pg/ml. Additionally, the minimum detection limits for IL-17 and IFN-γ was 6.3 and 6.9 pg/ml, respectively. The detection kit standard curves for IL-17 and IFN-γ were presented in Figure 1.

Assessment of degree of coronary artery stenosis

The Gensini score can be used to evaluate the degree of coronary artery stenosis; therefore, we determined Gensini scores in the patients and compared them to the IL-17 and IFN-γ levels in order to determine whether the IL-17 or IFN-γ levels can be used as auxiliary criteria for assessing the degree of coronary artery stenosis [23].

Statistical analysis

SPSS 19.0 statistical software (SPSS, Inc., Chicago, IL, USA) was used for data processing and analysis. Data were expressed as the mean ± standard deviation. Continuous clinical variables were compared between groups using the two-sample t-test. Correlation analysis was performed using the nonparametric Spearman correlation test. Additionally, differences among multiple groups were compared using one-way analysis of variance. Specific paired and unpaired tests and post hoc tests were used, and a P-value<0.05 was considered significant.

Results

Plasma IL-17 levels in patients with CHD before and after PCI

Before PCI, IL-17 levels did not differ between patients with AMI and UAP and were significantly higher in the AMI and UAP group than those in the control group (Figure 2A). After PCI, IL-17 levels were not significantly different among the 3 groups (Figure 2B). The IL-17 levels after PCI were significantly lower than those before PCI in the AMI and UAP groups (Figures 2C and 2D and Tables 2 and 3).

Plasma IFN-γ levels in patients with CHD before and after PCI

Both pre- and postoperatively, plasma IFN-γ levels were significantly higher in the AMI group than those in the UAP group, while the levels in both groups were higher than those in the control group (Figures 3A and 3B). IFN-γ levels significantly decreased in the AMI and UAP group after PCI compared to those before PCI (Figures 3C and 3D and Tables 2 and 3).

Table 2. Comparison of IL-17, IFN-γ levels among AMI group, UAP group and control group (x±s).

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>IL-17</th>
<th>IFN-γ</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UAP group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
AMI group 30 44.26 ± 16a 39.54 ± 5.12a
UAP group 30 38.66 ± 7.87a 35.24 ± 6.02ab
Control group 30 28.67 ± 14.39 24.54 ± 4.42

**Table 3. Comparison of IL-17 and IFN-γ levels between AMI group and UAP group before and after the standardized hospitalization (x̄ ± s).**

IFN-γ levels and Gensini integral in the UAP group (Table 5). A low correlation was observed between IL-17 and IFN-γ before treatment; however, no correlation was detected after treatment (Figure 4).

**Discussion**

Previous studies have shown that inflammation plays an important role in the occurrence and development of atherosclerosis and that it can cause vessel instability and rupture as well as acute events [1-3,5].

IL-17 has been shown to play a critical role in the pathogenesis of autoimmune diseases such as atherosclerosis by modulating immune cell trafficking and initiating inflammation [11,23]. Additionally, IL-17 has been shown to induce the production of various pro-inflammatory mediators and chemoattractants in monocytes/macrophages, such as TNF-α, IL-1β, monocytic chemoattractant protein-1, and intercellular adhesion molecule [13,23,24]. In the present study, IL-17 levels were significantly higher in the AMI and UAP groups than those in the control group. A study by Ji et al. showed that plasma IL-37 levels in patients with AMI and UAP were also significantly increased compared to those in the control and SAP groups [25]. However, no significant association was found between IL-17 levels and the degree of coronary artery stenosis (Figure 2). The relationship between IL-17 and IL-37 in the AMI and UAP groups was unclear, and these molecules may act synergistically with each other. IFN-γ has been shown to play important roles in foam cell formation, plaque development, and Th1-driven adaptive immune response, which promote the occurrence and development of CHD [21,22]. In the present study, IFN-γ levels were significantly higher in the AMI and UAP groups than those in the control group. Additionally, IFN-γ levels were higher in the AMI group than in the UAP group. However, no significant association was found between IFN-γ levels and the degree of coronary artery stenosis (Figure 3). Serum levels of IFN-γ showed no significant difference between the AMI group and UAP group [26]. Further studies including a larger number of cases are needed to determine this relationship.

Coronary atherosclerosis is an extremely complex process involving many factors. IL-17 and IFN-γ have been shown to synergistically affect vascular smooth muscle cells, thus promoting the occurrence and development of coronary atherosclerosis [12]. In this study, a low correlation was observed between IL-17 and IFN-γ before treatment; however, no correlation was found after treatment (Figure 4).

PCI is one of the most effective treatments for ACS. In the AMI and UAP groups, IL-17 and IFN-γ levels were significantly lower after PCI than before PCI.

**Relationship between IL-17 or IFN-γ levels and severity of CHD**

We detected a low correlation between IL-17 and IFN-γ levels among all groups before surgery (Table 4). No significant correlation between IL-17 or IFN-γ levels and the Gensini integral was found in patients with AMI. Similarly, no significant correlation was observed between the IL-17 and IL-17 or IFN-γ levels and severity of CHD.
Before the standardized hospitalization | After the standardized hospitalization
---|---
AMI group | 30 | 44.26 ± 16 | 31.37 ± 7.62<sup>a</sup> | 39.54 ± 16.37 | 34.15 ± 6.01<sup>a</sup>
UAP group | 30 | 38.66 ± 7.87 | 32.6 ± 10.08<sup>a</sup> | 35.24 ± 6.02 | 31.31 ± 5.39<sup>ab</sup>

<sup>a</sup>P<0.01, compared with the group before the standardized hospitalization; <sup>ab</sup>P<0.01, compared with AMI group after the standardized hospitalization

### Table 4. Correlation of serum IL-17 levels with serum IFN-γ levels in ACS patients (n=60).

<table>
<thead>
<tr>
<th>Correlation</th>
<th>IL-17 (pg.ml⁻¹)</th>
<th>R</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ (pg.ml⁻¹)</td>
<td>0.358</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

### Table 5. Correlation of Gensini scores with serum IL-17 levels or serum IFN-γ levels in ACS patients (n=60).

<table>
<thead>
<tr>
<th>Correlation</th>
<th>R</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum IL-17 levels</td>
<td>0.012</td>
<td>0.518</td>
</tr>
<tr>
<td>Serum IFN-γ levels</td>
<td>0.22</td>
<td>0.251</td>
</tr>
</tbody>
</table>

### Conclusion

IL-17 and IFN-γ may act synergistically in ACS. Moreover, the clinical symptoms in patients with ACS can be alleviated and the inflammation in the body can be reduced with PCI.

### Study Limitations

First, the sample size of the experiment was small. Second, the control group was not representative of a population without the disease because the absence of coronary lesions does not rule out the presence of other diseases. Finally, the results of this experiment were obtained using only enzyme-linked immunosorbent assay; no other test methods were used.

### Acknowledgments

The study received financial support from the National Natural Science Foundation of China (Project No. 81360028).

### Conflicts of Interest

All of the authors declare that they have no conflicts of interest regarding this paper.

### References


*Correspondence to
Guangsheng Du
Department of Cardiology
First Affiliated Hospital
School of Medicine
Shihezi University
PR China